(LOOTPRESS) – In the span of just a few days, the Food and Drug Administration approved two major cancer treatments — one for a rare genetic form of lung cancer, the other for aggressive bladder cancer.

For a state like West Virginia, where lung cancer rates are among the highest in the country and bladder cancer is more common than the national average, these announcements come with real implications for local patients and healthcare providers.

1. Hyrnuo (sevabertinib) – Targeted therapy for HER2-mutated lung cancer

On November 19, 2025, the FDA granted accelerated approval to Hyrnuo (sevabertinib) for adults with advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain mutations and who have already received prior systemic treatment.

See Full Page